This site is intended for healthcare professionals

VIALE-C trial of Venclexta + low-dose cytarabine versus LDAC + placebo did not meet its primary endpoint for patients with acute myeloid leukemia. AbbVie

Read time: 1 mins
Published:1st Mar 2020
Condition: Acute Myelogeous Leukemia (AML)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest